Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Curr Opin Pediatr. 2020 Dec 29;33(1):49–58. doi: 10.1097/MOP.0000000000000981

Figure 1. Clinically relevant inhibitors of the RAS pathway.

Figure 1.

Approved inhibitors are listed in green and inhibitors currently in development are listed in blue. Figure was created in Biorender.com.

Abbreviations: FTI, farnesyltransferase inhibitor; i, inhibitor; RTK, receptor tyrosine kinase; GTP, guanosine triphosphate; GDP, guanosine diphosphate.